In this webinar, the following aspects will be presented:

• Discovery and early development of “non-traditional” antibacterial approaches is a noticeable trend in the pre-clinical global pipeline
• These approaches include anti-virulence strategies, microbiome-modifying therapies, phages and others such as nanoparticles, immunotherapy and drug-resistance modulation
• Some of these approaches require novel preclinical efficacy models to predict clinical outcome
• Pathogen-specific or even patient-specific strategies dominate this field
• A major challenge will be to show efficacy in clinical trials

The presentation will be followed by a Q&A session with Ursula Theuretzbacher and Laura Piddock (GARDP).

Speaker: Ursula Theuretzbacher, CEFAIA, Austria

Moderator: Prabhavathi Fernandes, Chair of GARDP’s Scientific Advisory Committee

Register here for this live webinar.